Genetics
Dr. Sajuti Sarkar
Serum Protein Signatures Predict Clinical Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
A peer-reviewed scientific paper by Dr. Sajuti Sarkar et al. investigating serum protein signatures predict clinical response to immune checkpoint inhibitors in non-small cell lung cancer.
Dr. Sajuti SarkarJan 1, 2026
10 min read
589 views
Dr. Sajuti Sarkar
Assistant Professor, Biochemistry
Pabna Medical College, Bangladesh
Dr. Sajuti Sarkar is an Assistant Professor of Biochemistry at Pabna Medical College, Bangladesh. With an extensive background in medical biochemistry, diagnostic medicine, and clinical research, she has dedicated over a decade to teaching and mapping physiological experiences to biochemical pathways. Her research contributions span metabolic syndrome, trace element status in cardiovascular health, preeclampsia diagnostics, and novel cancer therapeutics.
Abstract
This peer-reviewed article, titled "Serum Protein Signatures Predict Clinical Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer", presents detailed research on serum protein signatures predict clinical response to immune checkpoint inhibitors in non-small cell lung cancer. Published in Sch Int J Biochem, 9(1): 17-22. DOI: 10.36348/sijb.2026.v09i01.002.
1. Introduction
The scientific study of serum protein signatures predict clinical response to immune checkpoint inhibitors in non-small cell lung cancer provides critical insights into modern diagnostics, clinical pathways, and medical biochemistry. This article details the research findings, patient cohort details, methodology, and direct clinical implications.
2. Introduction & Medical Context
The researchers led by Dr. Sajuti Sarkar, Dr. Susmita Sarkar, Dr. Bijoy Kumer Paul, Dr. Nirjhar Saha, Dr. Anu Rani Podder, Dr. Shah Md. Atiqul Haque, Dr. Faria Talukder address key aspects of this study within the scope of modern biomedical science. The team set out to discover critical pathways, physiological parameters, or clinical workflows that support better diagnosis and patient care.
3. Materials, Methods & Findings
Using structured methodologies, patient groups or sample cohorts were analyzed to measure key biochemical indicators and target endpoints. The results indicate statistically significant correlations that substantiate the researchers' core hypothesis. Further discussions evaluate these parameters in reference to international guidelines.
4. Future Directions
Future investigations should aim to extend sample size and incorporate prospective long-term follow-up clinical trials across multi-center cohorts.
5. Conclusion
In conclusion, this publication establishes strong evidence contributing to clinical awareness, diagnostic accuracy, or therapeutic protocols in biochemistry and public health.
References
- Sch Int J Biochem, 9(1): 17-22. DOI: 10.36348/sijb.2026.v09i01.002
Tags:GeneticsProtein SignaturesImmune Checkpoint InhibitorsLung Cancer
Share:
Discussion (0)
Join the conversationNo discussions yet. Be the first to share your thoughts!